Key Takeaways for ResMed Stock as of July 2026
- TIKR’s mid case model puts ResMed at a $288 target by 2030, a 42% total return from today’s price that works out to 9% annualized.
- Nineteen analysts cover the name: six buys, ten holds, one sell, one outperform and one no opinion.
- On April 30, ResMed announced a $340 million deal for Noctrix, a device business growing faster than ResMed with higher gross margins, expected to close June 1.
- ResMed stock still trades 30.59% below its June 2, 2026 peak drawdown level.
ResMed Stock Adds a New Growth Engine With the $340 Million Noctrix Acquisition
ResMed (RMD) closed its fiscal third quarter on April 30 with a $340 million deal already signed: the acquisition of Noctrix Health, a maker of a drug-free nerve stimulation device for restless legs syndrome, expected to close June 1, 2026. RLS is the third most common sleep disorder in the world, affecting 7% of adults worldwide and 17 million people in the U.S. alone, a patient population ResMed had never directly served before this deal.
On the Q3 earnings call, CEO Mick Farrell tied the acquisition directly to the math behind it: “its revenue growth rate is higher than ResMed’s and its gross margin is higher than ResMed’s, and we’re very excited about this tuck-in.” That combination, faster growth stacked on a richer margin profile, is what turns a small deal into a source of multi-year upside instead of a rounding error on the income statement.
Noctrix carries an estimated $24 million annual revenue run rate today, and ResMed expects the deal to trim non-GAAP EPS by $0.02 in the fourth quarter of fiscal 2026 as integration costs land before the revenue scales. ResMed funded the purchase out of the $520 million in free cash flow it generated in the March quarter alone, the kind of balance sheet strength that lets the company add a second growth leg without touching its streak of free cash flow conversion above 100%.
That is the development repricing ResMed stock right now. A company built almost entirely around obstructive sleep apnea just bought its way into a second underpenetrated disorder, using cash the core business throws off every quarter.
ResMed Stock Sits 31% Below Its June Peak Drawdown
ResMed stock hit a maximum drawdown of 38% on June 2, 2026, its worst stretch in years. Shares have clawed back some ground since, and the stock now trades 31% below that same reference peak even after the Noctrix deal added a new growth line to the story.
The drawdown has not closed despite the acquisition, which suggests the market has not yet credited ResMed with the RLS opportunity Farrell described on the call.
Wall Street stayed split on ResMed stock as of July 16: six buys, ten holds, one sell, one outperform and one no opinion among nineteen analysts. The mean target price sits at $249, implying 23% upside from the current $203 close. That target has slipped from $297 in March to its current level, tracking the stock’s decline rather than getting ahead of it.
TIKR Values ResMed Stock at $288, Pricing In the Noctrix Payoff
TIKR’s mid case model values ResMed stock at $288 by June 2030, implying a 42% total return from the current price of $203, or 9% annualized over four years.
That annualized return sits ahead of what most slow-growth health care compounders offer right now, positioning ResMed stock as a recovery story rather than a broken one. The model prices Noctrix as pure upside on top of a core sleep apnea business that keeps compounding on its own, a $340 million deal funded entirely out of quarterly free cash flow that adds a second growth leg without asking investors to underwrite a turnaround.
That is what makes $288 a floor case built on the existing franchise, not a stretch tied to a single new product line.
TIKR’s model points to $288 and a 42% return by 2030. Pull up the full forecast on TIKR for free →
Should You Invest in ResMed Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ResMed Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track ResMed Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze RMD stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
